Verenigde Staten - Engels - NLM (National Library of Medicine)

quo vademus - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 0.4 g in 1 g - broiler chickens: directions for use indication: lincomycin hydrochloride soluble powder is indicated for the control of necrotic enteritis caused by clostridium perfringens susceptible to lincomycin. dosage: administer at a dose rate of 64 mg of lincomycin per gallon of drinking water. treatment period: start medication as soon as the diagnosis of necrotic enteritis is determined. the drug should be administered for 7 consecutive days. administration: this packet will medicate 3000 gallons of drinking water providing 64 mg/gallon. note: after water medication is discontinued, a recommended control program for necrotic enteritis consists of feeding lincomycin premix at 2 grams lincomycin per ton of complete feed. swine: directions for use indication: lincomycin hydrochloride soluble powder is indicated for the treatment of swine dysentery (bloody scours). dosage: administer at a dose rate of 250 mg of lincomycin per gallon of drinking water. in clinical studies, this dose rate provided an average of

Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

nam pharma sdn. bhd. - lincomycin hcl; spectinomycin hcl -

Singapore - Engels - HSA (Health Sciences Authority)

yung shin pharmaceutical (singapore) pte ltd - lincomycin hcl eqv lincomycin - injection - 300 mg/ml - lincomycin hcl eqv lincomycin 300 mg/ml

Singapore - Engels - HSA (Health Sciences Authority)

zyfas pharma pte ltd - lincomycin hcl eqv lincomycin - injection - 300 mg/ml - lincomycin hcl eqv lincomycin 300 mg/ml

België - Engels - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

v.m.d. sa-nv - lincomycin hydrochloride - eq. lincomycin 100 mg/ml - solution for injection - 100 mg/ml - lincomycin hydrochloride - lincomycin - pig

België - Engels - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

v.m.d. sa-nv - lincomycin hydrochloride - eq. lincomycin 400 mg/g - powder for use in drinking water - 400 mg/ml - lincomycin hydrochloride - lincomycin - pig

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dox-al australia pty ltd - lincomycin as lincomycin hydrochloride - oral powder, pre-mix - lincomycin as lincomycin hydrochloride antibiotic active 800.0 mg/g - antibiotic & related - pigs | boar | gilt | piglet | sow | swine - serpulina (treponema) hyodysenteriae | swine dysentery

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - lincomycin as lincomycin hydrochloride; spectinomycin as spectinomycin sulfate tetrahydrate - oral powder, pre-mix - lincomycin as lincomycin hydrochloride antibiotic active 222.0 mg/g; spectinomycin as spectinomycin sulfate tetrahydrate antibiotic active 445.0 mg/g - antibiotic & related - pigs | poultry | boar | breeders | broiler | chickens | chicks | chooks | day old chicks | gilt | hatchlings | layers | piglet | - antibiotics - oral, parenteral | bacterial enteritis | chronic respiratory disease | infections of the respiratory tract | mycoplasma spp. | swine dysentery | acute respiratory infections | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | bronchiseptica | bronchitis | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | pharyngitis | pneumonia | post-weaning bacterial enterit | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection | tonsillitis

Australië - Engels - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.2 mg (equivalent: lincomycin, qty 300 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).